Key Highlights

  • TRex Bio (NASDAQ:TRXB) set IPO terms in an October 5, 2026 filing: 8.33 million shares at USD 14 to USD 16, which is about USD 125 million at the midpoint, with pricing expected on October 9.
  • Eli Lilly, already a principal shareholder, indicated interest in raising its stake to as much as 19.9% of TRex Bio (NASDAQ:TRXB) outstanding stock after the offering.
  • At the USD 15 midpoint, IPO calendar data put the Market Value of TRex Bio (NASDAQ:TRXB) near USD 411.7 million, using the proposed ticker, which can still change before trading starts.
  • J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow are joint book-running managers, and the company is described as an autoimmune and inflammatory disease biotech.

The Offering

TRex Bio, a biotech focused on autoimmune and inflammatory diseases, filed terms on October 5, 2026 to list on Nasdaq under the proposed ticker TRXB. The deal is 8.33 million shares at USD 14 to USD 16. At the USD 15 midpoint that raises about USD 124.95 million, simple arithmetic on the published terms, with a market value near USD 411.7 million based on IPO calendar data. Pricing is scheduled for October 9, 2026, though dates and ranges can change. The joint book-running managers are J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush PacGrow. Proposed symbols can change before trading begins, so the TRXB tag should be rechecked.

What Lilly's Interest Means

Eli Lilly (NYSE:LLY) is described as a principal Shareholder of TRex Bio and said it may be interested in buying shares that would lift its stake to up to 19.9% of the company after the IPO. An indication of interest is not a binding purchase order, and the final allocation depends on pricing and demand. A large strategic holder can signal confidence and Supply a potential partner, but it can also concentrate ownership and limit free float, the shares available to other investors. The filing summary did not state how many shares Lilly might buy, so the dollar value of the possible stake is not known.

Risks and What to Watch

Clinical-stage biotech IPOs carry high failure risk, since most drug candidates never reach approval. New listings often trade volatilely, later lock-up expirations can add selling pressure, and new shares dilute existing holders. Watch whether the range is raised or cut on October 9, how much Lilly actually buys and what the first trade shows. Rate pressure also matters, with 10-year Treasury yields near 5.3% weighing on long-duration growth stocks. Investors in TRex Bio (NASDAQ:TRXB) should read the final prospectus for cash runway, lead programs, trial plans and use of proceeds. Nothing here is Investment advice or a pricing forecast, and every figure should be rechecked against the final prospectus before trading begins.

Where Things Stand

Eli Lilly's possible 19.9% stake would make a large strategic investor an even bigger owner of TRex Bio (NASDAQ:TRXB), which is a notable vote of confidence but not a binding commitment. The final effect depends on pricing on October 9, the allocation Lilly receives and the company's trial progress. The USD 125 million midpoint raise is sizable for a biotech, though it carries the usual clinical-stage risks, dilution and lock-up considerations. The next catalyst is the pricing announcement.